Skip to main content
. 2016 Feb 1;9(2):211–220. doi: 10.1242/dmm.022715

Fig. 4.

Fig. 4.

Expression of Cre recombinase, and characterisation of recombined cells. (A-C) Double-labelling immunofluorescence detects cells expressing Cre recombinase following endoxifen administration in GLAST::CreERT2;ROSA26loxP/loxP reporter mice (A) or following Adeno-Cre-mediated recombination in ROSA26loxP/loxP reporter mice (B). Co-expression of GFAP and Cre recombinase appears yellow. Arrowheads indicate cells expressing both antigens. (D-I) Recombination of (D-F) GFAP-expressing and (G-I) nestin-expressing cells in the SVZ indicates effective endoxifen-mediated recombination in GLAST::CreERT2;ROSA26loxP/loxP reporter mice and confirms targeting of GFAP- and nestin-expressing progenitors. Arrowheads indicate cells expressing both antigens. No Cre expression and recombination was observed in controls (C,F,I). (J-L) Stem/progenitor cells of the SVZ give rise to neurospheres when cultured in permissive medium. Stem/progenitor cells that underwent recombination in vivo by intraventricular injection of endoxifen (J) or Adeno-Cre (K) give rise to recombined, β-galactosidase-expressing, progenies, which form blue spheres in the X-Gal assay. No recombination was observed in controls (L). Scale bar: 50 µm (A-I), 300 µm (J-L).